Relypsa (RLYP) Earns News Impact Rating of 0.13
Press coverage about Relypsa (NASDAQ:RLYP) has trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Relypsa earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 44.7140486147142 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Relypsa (RLYP) traded down $0.01 during trading on Friday, hitting $31.98. 107 shares of the company traded hands, compared to its average volume of 2,933,219. Relypsa has a one year low of $10.26 and a one year high of $32.12.
ILLEGAL ACTIVITY WARNING: “Relypsa (RLYP) Earns News Impact Rating of 0.13” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/relypsa-rlyp-earns-news-impact-rating-of-0-13/1752419.html.
Relypsa, Inc is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company’s technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address.
Receive News & Ratings for Relypsa Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.